BACKGROUND
Autoimmune nodopathies (ANs) are characterized by antibodies targeting nodal and paranodal proteins. Among AN, antibodies targeting neurofascin 186 and/or 140 are rarely reported in children. We describe the clinical features, electrophysiology, histopathology, and treatment outcomes of three children with anti-NF186/140 AN and isolated anti-NF140 AN.
METHODS
Retrospective case series.
RESULTS
Case 1 was 13-year boy with nephrotic syndrome presented with acute onset asymmetric progressive sensorimotor polyneuropathy with anti-NF140 antibody-positive AN. Cases 2 was a 7.6-year girl with chronic progressive symmetric distal weakness, subacute worsening, and had combined anti-NF186/140 antibody-positive AN. Case 3 was a 3.5-year-old boy with chronic progressive symmetric distal dominant weakness of all four limbs and had bulbar involvement with anti-NF140 antibody-positive AN. All three children had bilateral upper limb tremors. Electrophysiology demonstrated a non-length-dependent mixed axonal and demyelinating pattern of sensorimotor polyneuropathy. Nerve biopsy revealed axonal and mild myelin loss in all three cases, with lymphocytic infiltration in case 1. Treatment included steroids, intravenous immunoglobulins, plasma exchange, cyclophosphamide, and rituximab with graded response and improvement in the Inflammatory Neuropathy Cause and Treatment (INCAT) disability scores.
CONCLUSIONS
This case series expands the clinical spectrum of pediatric-onset anti-NF186/140 AN and isolated anti-NF140 AN. Recognition of key clinical clues, including tremors, bulbar involvement, and subacute progression, is essential to distinguish it from chronic inflammatory demyelinating polyneuropathy and Charcot-Marie-Tooth disease to facilitate timely antibody testing and targeted therapy.
AIM
To develop the Pediatric Autoimmune encephalitis Severity Scale (PASS) using expert consensus and the Delphi process, and validate it in children with autoimmune encephalitis.
METHOD
This prospective observational study enrolled children who underwent serial rating with PASS, the Clinical Assessment Scale in Autoimmune Encephalitis (CASE), and the modified Rankin Scale, at eight time points until 6 months of presentation. Clinical outcomes included the Pediatric Quality of Life Inventory (PedsQL) score (parent-rated) and developmental and intellectual outcome at 6 months. Interrater agreement, internal consistency, and correlations of PASS and CASE with clinical outcomes were compared.
RESULTS
There were 361 assessments in 27 children (11 females, 16 males) with autoimmune encephalitis (15 with antibody-negative autoimmune encephalitis, 11 with N-methyl-D-aspartate receptor antibody encephalitis, and one with steroid-responsive encephalopathy associated with autoimmune thyroiditis) with a median age at onset of 4 years (interquartile range = 3 years to 6 years 5 months). There was excellent interrater agreement for PASS and CASE with comparable intraclass correlation coefficients (0.984 vs 0.983). The worst PASS score was inversely correlated with the final PedsQL score (r = -0.42, p = 0.047). Factor analysis revealed distinct 'cognitive and behavioural' and 'disinhibition and excitability' dimensions in the PASS items.
INTERPRETATION
PASS is a severity assessment tool for autoimmune encephalitis in children and offers an alternative to adult scales, which may be difficult to use in children.
Priyanka Madaan, Suvasini Sharma, A. Easton et al.· Developmental Medicine & Chi...· 1 citation
We use cookies to run the site and, with your consent, for analytics and to show ads.
See our Cookie Policy.